The drug, a tissue plasminogen activator, is already licensed as a treatment for heart attack patients.

The more expensive drug, tissue plasminogen activator, is made by genetic engineering.

Tissue plasminogen activator should be given right away after the first symptoms of stroke start.

Hospitals will have to absorb Medicare heart patients' costs for use of the drug tissue plasminogen activator.

PAI-1, however, is the main inhibitor of the plasminogen activators.

Genetically engineered tissue plasminogen activator, at a cost of $2,200 a dose, comes most readily to mind.

The amount of colour developed during a fixed time is proportional to the tissue type plasminogen activator activity in the sample.

Little is known, however, about plasminogen activators in solid tumours of the upper gastrointestinal tract.

Neither study, however, directly measured the ascitic concentrations of tissue plasminogen activator.

Several attempts either to increase the efficacy of plasminogen activators or to reduce their clearance have been undertaken.

Plasminogen activator inhibitor-1 has been shown to interact with ORM1.

More recently, drugs such as tissue plasminogen activator, urokinase, and anisterplase have been used in its place.

The mast cell as site of tissue type plasminogen activator expression and fibrinolysis.

Fibrinogen alpha chain has been shown to interact with Tissue plasminogen activator.

Genentech has lost the British patent for what it expects to become its main product, tissue plasminogen activator.

Interferon, insulin, and tissue plasminogen activators are all believed to be suitable for this new technique.

Tissue type plasminogen activator antigen was measured essentially as described by Rijken et al.

For urokinase type plasminogen activator antigen in the stomach the opposite was observed.

Neither study, however, quantified the overall plasminogen activator activity of malignant ascites.

Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.

Plasminogen activator inhibitor-1, an inhibitor of fibrinolysis, is present in higher levels in people with obesity.

The agency has been asked to approve another new drug made by genetically altered bacteria, tissue plasminogen activator, to be used in treating heart attacks.

Indeed, tissue plasminogen activator, expected to be the first big-selling drug produced by the genetic engineering revolution, is off to a brisk start.

The others are human growth hormone, for children suffering from dwarfism, and tissue plasminogen activator, for heart attack victims.

Doctors are therefore reluctant to give the only drug shown to make a real difference, tPA, or tissue plasminogen activator.